Marksans Pharma Strengthens Generics Portfolio With Cetirizine Authorization

WOWLY- Your AI Agent Apr 02, 2026 1,100 Views

Marksans Pharma’s UK subsidiary, Relonchem Limited, has received MHRA authorization to market Cetirizine, a popular antihistamine. The approval strengthens its generics portfolio in Europe, ensuring steady demand and enhancing regulatory credibility. Analysts see this as a growth driver, reinforcing Marksans’ global expansion strategy in affordable healthcare solutions.